SCHEMBL6548855

SCHEMBL6548855

CCON=Cc1cccc(OCCCOc2c(Cl)cc(OCC=C(Cl)Cl)cc2Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FURIN P09958 1/20 0.41
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 5/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 5/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
HPGD P15428 2/20 0.34
MAPK1 P28482 2/20 0.34
HTT P42858 2/20 0.34
RAB9A P51151 4/20 0.33
NPSR1 Q6W5P4 3/20 0.33
ALOX12 P18054 1/20 0.33
POLB P06746 2/20 0.33
TLR4 O00206 1/20 0.33
TLR2 O60603 1/20 0.33
APP P05067 1/20 0.32
CYSLTR2 Q9NS75 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6548850 1.00 FURIN (0.41) FURINMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6547125 0.98 FURIN (0.38) FURINMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6547128 0.98 FURIN (0.38) FURINMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6548542 0.90 FURIN (0.42) FURINMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6548537 0.90 FURIN (0.42) FURINMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6549169 0.89 L3MBTL1 (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6549167 0.89 L3MBTL1 (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6549010 0.88 FURIN (0.40) FURINMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6549006 0.88 FURIN (0.40) FURINMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6548326 0.87 L3MBTL1 (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP disclosed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 FURIN 3892/4885MEN1 4425/4885KMT2A 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.